hy-p10102 Search Results


fas fasl signaling antagonist  (MedChemExpress)
93
MedChemExpress fas fasl signaling antagonist
Associations of CD8 + TIL subsets with (DN) TILs and clinical outcome (A) Dot color represents the communication probability of the specific ligand-receptor pairs, including TGF-β, IL-10, <t>and</t> <t>Fas-FasL</t> signaling between the indicated sender cluster and receiver clusters. (B) Representative histograms and statistical graph showing carboxyfluorescein succinimidyl ester (CFSE) dilution (left) and proliferation inhibition rates (right) of (DN) TILs with CD4 + and CD8 + naive T cells at a ratio of 4:1, 2:1, 1:1, and 1:2. The data are presented as mean ± SD, and three biological replicates were included. (C) Representative histograms and statistical graph showing CFSE dilution (left) and proliferation inhibition rates (right) of (DN) TILs with CD4 + and CD8 + naive T cells at a 1:1 ratio with neutralizing antibodies against TGF-β and IL-10, as well as the presence or absence of a Fas-FasL signaling antagonist. The data are presented as mean ± SD, and three biological replicates were included. p values were evaluated by t test (two-sided). ∗∗ p < 0.01; ∗∗∗ p < 0.001. (D) Bubble plot showing the correlation between the frequency of (DN) TILs and other TIL subsets in TIL infusion products ( n = 26). p values were determined by Spearman correlation analysis. ∗ p < 0.05. (E) Dot plot showing the correlation between the frequency of (DN) TILs and CD8 + TILs in TIL infusion products ( n = 26). p values were determined by Spearman correlation analysis. (F) Representative histograms and statistical graph showing CFSE dilution (left) and proliferation inhibition rates (right) of (DN) TILs with autologous expanded CD8 + TILs at ratios of 4:1, 2:1, and 1:1. Conventional CD4 + (i)Tregs were included as a control. The data are presented as mean ± SD, and three biological replicates were included. (G–K) Kaplan-Meier survival curves of PFS and OS in NPC patients stratified according to the abundance (high vs. low) of total CD8 + TILs (G), C2_proliferation_CD8_T_cells-PCNA (H), C4_MHC_II_CD8_T_cells (I), C6_proliferation_CD8_T_cells-TOP2A (J), and C12_tissue_resident_memory_CD8_T_cells (K) inferred from (sc)RNA sequencing data ( n = 26). p values were determined based on the two-sided log rank test. See also and .
Fas Fasl Signaling Antagonist, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/hy-p10102/Kp7-6/pmc12147895-345-33-38
Average 93 stars, based on 1 article reviews
fas fasl signaling antagonist - by Bioz Stars, 2026-10
93/100 stars
  Buy from Supplier

Image Search Results


Associations of CD8 + TIL subsets with (DN) TILs and clinical outcome (A) Dot color represents the communication probability of the specific ligand-receptor pairs, including TGF-β, IL-10, and Fas-FasL signaling between the indicated sender cluster and receiver clusters. (B) Representative histograms and statistical graph showing carboxyfluorescein succinimidyl ester (CFSE) dilution (left) and proliferation inhibition rates (right) of (DN) TILs with CD4 + and CD8 + naive T cells at a ratio of 4:1, 2:1, 1:1, and 1:2. The data are presented as mean ± SD, and three biological replicates were included. (C) Representative histograms and statistical graph showing CFSE dilution (left) and proliferation inhibition rates (right) of (DN) TILs with CD4 + and CD8 + naive T cells at a 1:1 ratio with neutralizing antibodies against TGF-β and IL-10, as well as the presence or absence of a Fas-FasL signaling antagonist. The data are presented as mean ± SD, and three biological replicates were included. p values were evaluated by t test (two-sided). ∗∗ p < 0.01; ∗∗∗ p < 0.001. (D) Bubble plot showing the correlation between the frequency of (DN) TILs and other TIL subsets in TIL infusion products ( n = 26). p values were determined by Spearman correlation analysis. ∗ p < 0.05. (E) Dot plot showing the correlation between the frequency of (DN) TILs and CD8 + TILs in TIL infusion products ( n = 26). p values were determined by Spearman correlation analysis. (F) Representative histograms and statistical graph showing CFSE dilution (left) and proliferation inhibition rates (right) of (DN) TILs with autologous expanded CD8 + TILs at ratios of 4:1, 2:1, and 1:1. Conventional CD4 + (i)Tregs were included as a control. The data are presented as mean ± SD, and three biological replicates were included. (G–K) Kaplan-Meier survival curves of PFS and OS in NPC patients stratified according to the abundance (high vs. low) of total CD8 + TILs (G), C2_proliferation_CD8_T_cells-PCNA (H), C4_MHC_II_CD8_T_cells (I), C6_proliferation_CD8_T_cells-TOP2A (J), and C12_tissue_resident_memory_CD8_T_cells (K) inferred from (sc)RNA sequencing data ( n = 26). p values were determined based on the two-sided log rank test. See also and .

Journal: Cell Reports Medicine

Article Title: Tumor-infiltrated double-negative regulatory T cells predict outcome of T cell-based immunotherapy in nasopharyngeal carcinoma

doi: 10.1016/j.xcrm.2025.102096

Figure Lengend Snippet: Associations of CD8 + TIL subsets with (DN) TILs and clinical outcome (A) Dot color represents the communication probability of the specific ligand-receptor pairs, including TGF-β, IL-10, and Fas-FasL signaling between the indicated sender cluster and receiver clusters. (B) Representative histograms and statistical graph showing carboxyfluorescein succinimidyl ester (CFSE) dilution (left) and proliferation inhibition rates (right) of (DN) TILs with CD4 + and CD8 + naive T cells at a ratio of 4:1, 2:1, 1:1, and 1:2. The data are presented as mean ± SD, and three biological replicates were included. (C) Representative histograms and statistical graph showing CFSE dilution (left) and proliferation inhibition rates (right) of (DN) TILs with CD4 + and CD8 + naive T cells at a 1:1 ratio with neutralizing antibodies against TGF-β and IL-10, as well as the presence or absence of a Fas-FasL signaling antagonist. The data are presented as mean ± SD, and three biological replicates were included. p values were evaluated by t test (two-sided). ∗∗ p < 0.01; ∗∗∗ p < 0.001. (D) Bubble plot showing the correlation between the frequency of (DN) TILs and other TIL subsets in TIL infusion products ( n = 26). p values were determined by Spearman correlation analysis. ∗ p < 0.05. (E) Dot plot showing the correlation between the frequency of (DN) TILs and CD8 + TILs in TIL infusion products ( n = 26). p values were determined by Spearman correlation analysis. (F) Representative histograms and statistical graph showing CFSE dilution (left) and proliferation inhibition rates (right) of (DN) TILs with autologous expanded CD8 + TILs at ratios of 4:1, 2:1, and 1:1. Conventional CD4 + (i)Tregs were included as a control. The data are presented as mean ± SD, and three biological replicates were included. (G–K) Kaplan-Meier survival curves of PFS and OS in NPC patients stratified according to the abundance (high vs. low) of total CD8 + TILs (G), C2_proliferation_CD8_T_cells-PCNA (H), C4_MHC_II_CD8_T_cells (I), C6_proliferation_CD8_T_cells-TOP2A (J), and C12_tissue_resident_memory_CD8_T_cells (K) inferred from (sc)RNA sequencing data ( n = 26). p values were determined based on the two-sided log rank test. See also and .

Article Snippet: To evaluate the suppression mechanism of DN TILs, neutralizing antibodies targeting TGF-β (5 μg/mL; Sanyou Biopharmaceuticals Co. Ltd, CHB215) and IL-10 (5 μg/mL; Sanyou Biopharmaceuticals Co. Ltd, CHA915) were added, along with a Fas-FasL signaling antagonist (10 μM; MedChemExpress, HY- P10102 ) and GITR inhibitor (20 nM; KKL Med Inc., KM2426) at an effector-to-target (E:T) ratio of 1:1.

Techniques: Inhibition, Control, RNA Sequencing